vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Streamex Corp. (STEX). Click either name above to swap in a different company.
Streamex Corp. runs the higher net margin — 155840.0% vs 8.6%, a 155831.4% gap on every dollar of revenue. Over the past eight quarters, Streamex Corp.'s revenue compounded faster (NaN% CAGR vs NaN%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
LIVN vs STEX — Head-to-Head
Income Statement — Q4 2025 vs Q3 2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $-10.0K |
| Net Profit | $30.9M | $-15.6M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | 61130.0% |
| Net Margin | 8.6% | 155840.0% |
| Revenue YoY | 12.1% | — |
| Net Profit YoY | -44.7% | -714.2% |
| EPS (diluted) | $0.57 | $-0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | — | ||
| Q3 25 | $357.8M | $-10.0K | ||
| Q2 25 | $352.5M | $13.0K | ||
| Q1 25 | $316.9M | — | ||
| Q4 24 | $321.8M | $13.0K | ||
| Q3 24 | $318.1M | $0 | ||
| Q2 24 | $318.6M | $13.0K | ||
| Q1 24 | $294.9M | $14.0K |
| Q4 25 | $30.9M | — | ||
| Q3 25 | $26.8M | $-15.6M | ||
| Q2 25 | $27.2M | $-20.4M | ||
| Q1 25 | $-327.3M | — | ||
| Q4 24 | $55.9M | $-1.1M | ||
| Q3 24 | $33.0M | $-1.9M | ||
| Q2 24 | $16.3M | $-3.9M | ||
| Q1 24 | $-41.9M | $-3.4M |
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — | ||
| Q1 24 | 70.3% | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 15.1% | 61130.0% | ||
| Q2 25 | 15.4% | -156653.8% | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 11.5% | -9100.0% | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 12.6% | -40707.7% | ||
| Q1 24 | 5.5% | -24550.0% |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 7.5% | 155840.0% | ||
| Q2 25 | 7.7% | -156707.7% | ||
| Q1 25 | -103.3% | — | ||
| Q4 24 | 17.4% | -8453.8% | ||
| Q3 24 | 10.4% | — | ||
| Q2 24 | 5.1% | -30115.4% | ||
| Q1 24 | -14.2% | -24300.0% |
| Q4 25 | $0.57 | — | ||
| Q3 25 | $0.49 | $-0.47 | ||
| Q2 25 | $0.50 | $-0.74 | ||
| Q1 25 | $-6.01 | — | ||
| Q4 24 | $1.04 | $0.03 | ||
| Q3 24 | $0.60 | $-0.12 | ||
| Q2 24 | $0.30 | $-0.30 | ||
| Q1 24 | $-0.78 | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | — |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $-7.0M |
| Total Assets | $2.6B | $130.5M |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | — | ||
| Q1 24 | $309.2M | — |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $-7.0M | ||
| Q2 25 | $1.1B | $-3.6M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.3B | $-1.5M | ||
| Q3 24 | $1.3B | $-405.0K | ||
| Q2 24 | $1.2B | $-6.0K | ||
| Q1 24 | $1.2B | $-4.3M |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $130.5M | ||
| Q2 25 | $2.5B | $109.7M | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.5B | $842.0K | ||
| Q3 24 | $2.5B | $1.4M | ||
| Q2 24 | $2.5B | $3.1M | ||
| Q1 24 | $2.5B | $1.6M |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $-5.0M |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | — | ||
| Q3 25 | $85.1M | $-5.0M | ||
| Q2 25 | $62.9M | $-1.3M | ||
| Q1 25 | $24.0M | — | ||
| Q4 24 | $78.7M | $-474.0K | ||
| Q3 24 | $51.0M | $-1.5M | ||
| Q2 24 | $43.4M | $-1.5M | ||
| Q1 24 | $10.0M | $-1.3M |
| Q4 25 | $50.2M | — | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $47.8M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $68.3M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $31.2M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
STEX
Segment breakdown not available.
